AltMountain

Sphera Funds Management LTD.

Tel Aviv, Israel · CRD 312614
Hedge fund managerExempt reporting

Sphera Funds Management LTD. is an exempt reporting adviser based in Tel Aviv, Israel that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $849.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +31.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.9% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
—Form ADV Item 5.F
Gross assets of private funds
$849.7 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
—Form ADV Item 5.A
Registration
Exempt reporting adviserCRD 312614
Latest Form ADV
03/17/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+31.3%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+81.9%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$698.8 million97 positions, 2026-06-30
$80$131$182Q3 2024Q1 2025Q3 2025Q1 202613F est. $182S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+16.3%+14.8%
Q1 2026+12.9%-4.6%
Q4 2025+23.6%+2.4%
Q3 2025+28.9%+7.8%
Q2 2025+8.1%+10.4%
Q1 2025-15.0%-4.5%
Q4 2024-8.1%+2.1%
Q3 2024+2.9%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 100 share positions ($660,392,803) reported by Sphera Funds Management LTD. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Mineralys Therapeutics Inc5.03%
  • Teva Pharmaceutical Inds LTD4.92%
  • Alnylam Pharmaceuticals Inc4.51%
  • Cytokinetics Inc3.61%
  • Ishares TR3.19%
  • Bridgebio Pharma Inc3.11%
  • Tower Semiconductor LTD2.92%
  • Syndax Pharmaceuticals Inc2.87%
  • Biomarin Pharmaceutical Inc2.66%
  • Biogen Inc2.59%
StockValue% of 13F portfolioSharesShares vs prior quarter
Mineralys Therapeutics Inc$33,218,3675.03%1,321,861-10.08%
Teva Pharmaceutical Inds LTD$32,522,7674.92%821,282New
Alnylam Pharmaceuticals Inc$29,757,3374.51%120,602+1,016.69%
Cytokinetics Inc$23,852,6313.61%361,897+64.51%
Ishares TR$21,039,6803.19%37,000New
Bridgebio Pharma Inc$20,510,9793.11%311,717+27.05%
Tower Semiconductor LTD$19,272,4182.92%84,740-21.73%
Syndax Pharmaceuticals Inc$18,936,8262.87%1,007,278-0.72%
Biomarin Pharmaceutical Inc$17,594,7602.66%293,246-10.75%
Biogen Inc$17,113,3462.59%75,763-21.59%
Cogent Biosciences Inc$16,059,3112.43%501,540+9.19%
Nova LTD$15,039,7492.28%39,044+55.13%
Madrigal Pharmaceuticals Inc$12,999,6481.97%25,795+48.09%
Meta Platforms Inc$11,747,9161.78%16,200New
Immatics N.V$11,455,5471.73%1,304,732+81.20%
Sanofi SA$11,112,1031.68%269,515Unchanged
Astrazeneca PLC$11,065,5391.68%68,530+9.60%
Maze Therapeutics Inc$9,955,7081.51%366,288-12.28%
Eli Lilly & Co$9,302,9231.41%8,040Unchanged
Kla Corp$8,814,7351.33%45,220New
Lam Research Corp$8,508,4091.29%25,900+40.23%
Pfizer Inc$8,156,7201.24%286,000Unchanged
Ideaya Biosciences Inc$8,122,2951.23%211,408+7.64%
Rhythm Pharmaceuticals Inc$7,655,2861.16%80,400Unchanged
Johnson & Johnson$7,632,7191.16%28,831Unchanged
Tango Therapeutics Inc$7,591,0381.15%304,250+19.67%
Disc Medicine Inc$7,510,7491.14%114,738+80.58%
Vor Biopharma Inc$7,315,5961.11%383,417-7.92%
Applied Matls Inc$7,312,7341.11%14,300+29.53%
Abivax SA$7,299,3581.11%73,716New
Pharvaris N V$7,286,0841.10%229,700New
Camtek LTD$7,265,7001.10%46,800New
Merck & Co Inc$7,062,0661.07%48,600-17.06%
Nuvectis Pharma Inc$6,830,7361.03%323,425-15.54%
Novartis AG$6,412,8430.97%45,000-10.00%
Abbvie Inc$5,821,9470.88%22,256-26.44%
First Tracks Biotherapeutics$5,678,7990.86%160,237+474.82%
Trevi Therapeutics Inc$5,517,9110.84%385,329-22.78%
Satellos Bioscience Inc$5,428,8650.82%638,690-2.13%
Annexon Inc$5,171,9660.78%1,222,687New
Ultragenyx Pharmaceutical In$5,089,8040.77%338,643-42.46%
Climb Bio Inc$4,780,0880.72%416,747-13.85%
Cybin Inc$4,770,3760.72%388,151-76.05%
Oric Pharmaceuticals Inc$4,706,1890.71%349,383-53.60%
Revolution Medicines Inc$4,597,8240.70%22,400Unchanged
Novo-nordisk A S$4,574,8650.69%120,677Unchanged
Enliven Therapeutics Inc$4,573,2280.69%99,765-11.53%
Tenax Therapeutics Inc$4,376,6650.66%2,315,696+1,826.54%
Tectonic Therapeutic Inc$4,365,4310.66%187,438New
GSK PLC$4,335,3000.66%90,000-11.76%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 22 new positions, 19 sold out, 30 increased, 34 reduced and 14 unchanged.

Number of positions (a count, not dollars)

  • New positions22
  • Increased30
  • Unchanged14
  • Reduced34
  • Sold out19

New positions

StockValueShares
Teva Pharmaceutical Inds LTD$32,522,767821,282
Ishares TR$21,039,68037,000
Meta Platforms Inc$11,747,91616,200
Kla Corp$8,814,73545,220
Abivax SA$7,299,35873,716
Pharvaris N V$7,286,084229,700
Camtek LTD$7,265,70046,800
Annexon Inc$5,171,9661,222,687
Tectonic Therapeutic Inc$4,365,431187,438
Crescent Biopharma Inc.$4,081,086279,718
Adlai Nortye LTD$3,770,624235,664
Q32 Bio Inc$3,712,180448,873
Rapport Therapeutics Inc$3,360,000100,000
Latigo Biotherapeutics Inc$3,208,404192,120
Applied Optoelectronics Inc$3,197,16532,210
Pyxis Oncology Inc$1,605,370689,000
Erasca Inc$1,600,872109,200
Jade Biosciences Inc$1,482,682105,529
Intellia Therapeutics Inc$1,088,41590,250
Quoin Pharmaceuticals LTD$1,077,227236,234

Sold out

StockValue at Jun 30, 2026Shares held then
Teva Pharmaceutical Inds LTD$50,822,7781,500,082
Insmed Inc$12,666,456118,800
Solaredge Technologies Inc$7,747,1904,000,000
Xenon Pharmaceuticals Inc$6,337,800105,000
Zenas Biopharma Inc$5,858,567230,834
Forte Biosciences Inc$5,305,976249,693
Vistra Corp$4,671,65429,450
Talen Energy Corp$4,662,99512,135
Global X FDS$4,454,766195,900
Biocryst Pharmaceuticals Inc$4,220,510422,051
Generate Biomedicines Inc$4,133,150245,000
Kodiak Sciences Inc$3,186,77281,796
Ormat Technologies Inc$3,050,83428,015
Biohaven LTD$2,446,823164,437
Constellation Energy Corp$2,446,4459,850
Verastem Inc$2,416,654632,632
Structure Therapeutics Inc$1,534,96228,600
Curis Inc$1,033,71798,996
Shattuck Labs Inc$600,03986,461

Largest increases

StockChange in sharesChangeValue nowShares now
Alnylam Pharmaceuticals Inc+109,802+1,016.69%$29,757,337120,602
Cytokinetics Inc+141,910+64.51%$23,852,631361,897
Nova LTD+13,875+55.13%$15,039,74939,044
Immatics N.V+584,675+81.20%$11,455,5471,304,732
First Tracks Biotherapeutics+132,361+474.82%$5,678,799160,237
Bridgebio Pharma Inc+66,371+27.05%$20,510,979311,717
Madrigal Pharmaceuticals Inc+8,376+48.09%$12,999,64825,795
Tenax Therapeutics Inc+2,195,496+1,826.54%$4,376,6652,315,696
Disc Medicine Inc+51,200+80.58%$7,510,749114,738
Evommune Inc+368,000+1,626.02%$3,226,620390,632
Lam Research Corp+7,430+40.23%$8,508,40925,900
Applied Matls Inc+3,260+29.53%$7,312,73414,300
Cogent Biosciences Inc+42,200+9.19%$16,059,311501,540
Tango Therapeutics Inc+50,000+19.67%$7,591,038304,250
Astrazeneca PLC+6,000+9.60%$11,065,53968,530
Immix Biopharma Inc+85,800+31.78%$3,702,099355,800
Ovid Therapeutics Inc+247,000+18.26%$3,984,0001,600,000
Corvus Pharmaceuticals Inc+53,200+21.72%$3,434,815298,161
Ideaya Biosciences Inc+15,000+7.64%$8,122,295211,408
Upstream Bio Inc+106,131+48.31%$1,717,129325,831

Largest reductions

StockChange in sharesChangeValue nowShares now
Cybin Inc-1,232,602-76.05%$4,770,376388,151
Oric Pharmaceuticals Inc-403,600-53.60%$4,706,189349,383
Tower Semiconductor LTD-23,525-21.73%$19,272,41884,740
Celldex Therapeutics Inc New-149,772-62.18%$2,952,42191,096
Biogen Inc-20,863-21.59%$17,113,34675,763
Ultragenyx Pharmaceutical In-249,851-42.46%$5,089,804338,643
Mineralys Therapeutics Inc-148,110-10.08%$33,218,3671,321,861
Harmony Biosciences Hldgs In-80,900-45.79%$3,759,65595,763
Acadia Pharmaceuticals Inc-154,447-43.32%$4,072,053202,087
Biomarin Pharmaceutical Inc-35,304-10.75%$17,594,760293,246
Abbvie Inc-8,000-26.44%$5,821,94722,256
Cytomx Therapeutics Inc.-753,605-85.73%$341,074125,395
Trevi Therapeutics Inc-113,700-22.78%$5,517,911385,329
Merck & Co Inc-10,000-17.06%$7,062,06648,600
Maze Therapeutics Inc-51,276-12.28%$9,955,708366,288
Nuvectis Pharma Inc-59,520-15.54%$6,830,736323,425
Alpha Cognition Inc-130,262-23.87%$3,739,986415,554
Scholar Rock Hldg Corp-22,000-23.34%$3,491,84572,265
Skye Bioscience Inc-591,664-87.15%$140,49487,264
Climb Bio Inc-67,000-13.85%$4,780,088416,747

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Tenax Therapeutics, Inc.13G amendment7.09%2,663,296Oct 13, 2026SEC.gov ↗
ProMIS Neurosciences Inc.13G amendment7.78%—Feb 5, 2026SEC.gov ↗
Outlook Therapeutics, Inc.13G amendment4.69%3,153,856Feb 5, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 5, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (4)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Mar 6, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠